Latest Amgen Inc (AMGN) Headlines Chelsea Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Amgen Inc (AMGN) Headlines

Chelsea Therapeutics Posts Wider Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:41PM CDT
Chelsea Therapeutics International Ltd. (CHTP) reported fourth quarter 2013 loss of 7 cents per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 3 cents per share.

Midday Glance: Biotechnology companies
AP - Wed Mar 12, 12:28PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:

Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Bright Outlook at Ligand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:30AM CDT
Ligand provided a rosy outlook at the 2014 Roth Healthcare conference.

Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.

Early Glance: Biotechnology companies
AP - Wed Mar 12, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

Oxigene Surprises With Positive Ovarian Cancer Study Success
at The Street - Wed Mar 12, 5:00AM CDT
A combination of Oxigene's Zybrestat and Roche's Avastin delayed the regrowth of tumors in women with advanced ovarian cancer.

Is Merck a Buy at Current Price Levels?
Peter Stephens, The Motley Fool - Motley Fool - Tue Mar 11, 7:58PM CDT
Shares in Merck have had a strong three months, up 15% while the S&P 500 has posted gains of just under 4%. However, since the bull market of March 2009 kicked off five years ago, Merck is considerably behind the wider index. While the S&P...

Final Glance: Biotechnology companies
AP - Tue Mar 11, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:

The Cancer Monoclonal Antibodies Market is Estimated at US$ 24 Billion, and is expected to Grow to Around US$ 34 Billion by 2017
M2 - Tue Mar 11, 10:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghw3bj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" report to their offering. Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies. Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs. In this report, the authors have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs. Through this pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs. Companies Mentioned: - Amgen - Bristol-Myers Squibb - Eli Lilly - Genmab - GlaxoSmithKline - Roche - Seattle Genetics - Spectrum Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/gh...monoclonal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Investigation Report on China's Epoetin Alfa Market
M2 - Tue Mar 11, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5rt9tv/investigation) has announced the addition of the "Investigation Report on China Epoetin Alfa Market, 2009-2018" report to their offering. Epoetin alfa refers to erythropoietin (EPO), a hormone-like substance secreted by kidney and liver that stimulates erythropoiesis. Indications of EPO approved in China are renal anemia, anemia after chemotherapy and surgery perioperative red blood cell mobilization. The ratio between EPO used in renal dialysis and in chemotherapy is 3:1. Growth rate of EPO used in chemotherapy is about 20% to 25%, which is higher than that of renal dialysis. However, in the international market, more EPO is used in anemia after chemotherapy than in renal dialysis. This indicates huge market space for EPO used in anemia after chemotherapy in China. Originally developed by Amgen Inc., epoetin alfa was approved to the U.S. in June 1989 by FDA with the trade name ""Epogen"". It is sold in over 40 countries now. Amgen is the only authorized product sold in the U.S. hemodialysis market. However, in other indications' market in the U.S., due to financial shortage, Amgen gave the marketing right of Epogen to Kirin-Amgen, Inc. (joint venture of Amgen and Kirin). The company then authorized Ortho Pharmaceutical Corporation of Johnson & Johnson to sell the product with the brand name ""Procrit"". In other countries including Chinese mainland, Taiwan and Japan, the drug is sold by Kirin Inc. and Johnson & Johnson with the trade names ""Espo"" and ""Eprex"" respectively. Both the companies are authorized by Kirin-Amgen. Key Topics Covered: 1 Relevant Concepts of Epoetin Alfa 2 Market Overview of Epoetin Alfa in China 3 Investigation on Sales Value of Epoetin Alfa in China, 2009-2013 4 Investigation on Market Share of Major Epoetin Alfa Manufacturers in China, 2009-2013 5 Investigation on Market Size of Epoetin Alfa by Dosage Form in China, 2009-2013 6 Reference Price of Epoetin Alfa Produced by Different Enterprises in China Hospital Market 7 Analysis on Major Epoetin Alfa Manufacturers in China, 2009-2013 8 Prospect of China Epoetin Alfa Market, 2014-2018 Companies Mentioned - Shenyang Sunshine Pharmaceutical Co., Ltd. - Kirin Brewery Company, Limited - NCPC GeneTech Biotechnology development Co., Ltd. - Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. - Beijing Sihuan Biopharmaceutical Co., Ltd. - Shanghai Chemo Wanbang Biopharmaceutical Co., Ltd. - Harbin Pharmaceutical Group Bio-Engineering Co., Ltd. - Shandong Kexing Bioproducts Co., Ltd. For more information visit http://www.researchandmarkets.com/research/5r...estigation

Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind
PR Newswire - Tue Mar 11, 10:32AM CDT
On Monday, March 10, 2014, the NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones Industrial Average fell 0.21% to 16,418.68, and the S&P 500 closed at 1,877.17, down 0.05%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 689.78, up 0.39%, and has gained 4.92% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN), Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation (NASDAQ: MNKD). Free research on these four companies can be accessed at:

Today’s Top Biotech Stories: Myriad Genetics, Bayer, Amgen, and Synta
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 11, 9:27AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Myriad Genetics...

Stock Market News for March 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:06AM CDT
Benchmarks finished Monday’s trading session nearly flat after recovering from day’s initial losses caused due to a drop in China’s export data and less-than-expected growth in Japan’s economy

Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
PR Newswire - Tue Mar 11, 8:08AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

The US Specialty Pharmaceutical Market Report: 2013 Edition
M2 - Tue Mar 11, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8bkqqb/the_us_specialty) has announced the addition of the "The US Specialty Pharmaceutical Market Report: 2013 Edition" report to their offering. Specialty pharmaceuticals are defined as a new, rapidly growing drugs and biologics that are manufactured as a result of continued advancements in drug technology and design. These pharmaceuticals are specialized, high cost products which can be difficult to administer and may require patient monitoring. Specialty pharmaceuticals are utilized as complex therapies for complex chronic diseases such as cancer, hemophilia, multiple sclerosis, HIV, hepatitis C, apart from others. Some of the specialized drugs that are used for treating such conditions meet all the three H's: High Cost, High Complexity and High Touch and they require extensive education for safe and cost-effective use. The specialty pharmaceuticals are mostly injectable or infused medicines but may also encompass oral medications. Specialty pharmacy is a special class of provider that are primarily responsible for distributing and dispensing the pharmaceutical as specialty pharmaceutical require specialized shipping and temperature-controlled storing and handling. Specialty pharmacy can be owned by stand-alone companies or large pharmacy chains. However, some drug wholesalers are also capable of shipping the specialty pharmaceuticals. There exists a substantial incentive for companies to research and develop products that address the unmet need of the patients as the specialty pharmaceutical market has the ability to sustain the high cost of these products thereby additionally offering a business perspective for the biopharmaceutical companies. The key factors driving growth of the US specialty pharmaceutical industry include accelerating US aging population, ameliorating economic condition, increased life expectancy, and increasing healthcare expenditure. Some of the noteworthy trends and developments of this industry include rising Medicare enrollment, novel specialty products in pipeline, conversion of patents to generic drugs, increased spending on specialty drugs and ongoing merger & acquisition activities. However, the growth of the industry is being hindered by lack of rigorous clinical trials, sluggish pace of innovation and inappropriate use of therapeutic drugs. The specialty pharmaceutical market witnesses fierce competition with numerous top notch players. The fierce competition prevailing in the US specialty pharmaceutical industry has been studied on a number of parameters such as competing drugs, mail pharmacies and distributors. Company profiles of leading players are also presented in the report. Key Topics Covered 1. Overview 1.1 Specialty Pharmaceuticals Vs Traditional Drugs 1.2 Applications of Specialty Pharmaceuticals 1.3 Specialty Pharmacy Services 1.4 Specialty Product Distribution 1.5 Specialty Pharma Manufacturer Services 1.6 Value Proposition of Specialty Pharmacy 2. Market Size 2.1 Pharmaceutical Market 2.2 The US Specialty Pharmaceutical Market 3. Market Dynamics 3.1 Growth Drivers 3.2 Trends and Developments 3.3 Challenges 4. Competitive Landscape 4.1 Competition by Drugs 4.2 Competition by Mail Pharmacy 4.3 Competition by Specialty Distributor 5. Company Profiles 6. Market Outlook 6.1 Market Forecast 6.2 Forecast Methodology Companies Mentioned - Amgen - Eli Lilly and Company - Johnson & Johnson - Novo Nordisk - Pfizer - Roche For more information visit http://www.researchandmarkets.com/research/8b..._specialty About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
PR Newswire - Tue Mar 11, 2:30AM CDT
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival. The safety findings were consistent with the known profile of sorafenib. Data from this study will be submitted for presentation at an upcoming scientific congress.

Amgen Inc. (AMGN) Stock Research Links

AMGN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 111

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 63

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 137

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading
Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 56

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 115

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 186

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Fresha Pushes Beauty Bookings Into AI Search Channels

Updated Category News Views 45

A haircut search is turning into a distribution fight, and Fresha has planted itself squarely in the middle of it. The company’s new Partner Network pushes its beauty and wellness marketplace beyond its own app and website into Google Search, Google Maps, Google’s AI experiences, ChatGPT, Claude, and eventually Alexa. That sounds like another glossy AI announcement...

Continue Reading
MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 52

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 139

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 134

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading

Top 5 Most Recently Viewed Articles

Whataburger Announces Leadership Transition with New CEO

Updated Category News Views 664

Whataburger Announces CEO Retirement and Leadership Transition Whataburger is making headlines with the news that Chief Executive Officer Ed Nelson will retire at the end of this year. This marks the conclusion of a significant chapter in the company’s journey. Over his two-decade tenure, Ed's leadership has profoundly impacted Whataburger's growth and expansion. Ed...

Continue Reading
Important Insights on BBAI Class Action and Shareholder Rights

Updated Category News Views 255

Understanding the Class Action Lawsuit for BigBear.ai Holdings, Inc. BigBear.ai Holdings, Inc. (NYSE: BBAI) is currently facing legal scrutiny as a class action lawsuit has been filed on behalf of shareholders who purchased the company's securities between specific periods of interest. Legal representatives are urging shareholders who believe they were adversely affected...

Continue Reading
Piramal Pharma Limited Delivers Strong Financial Growth in FY25

Updated Category News Views 480

Piramal Pharma Limited Announces Impressive Q2 and H1 FY25 Results Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635), a prominent player in the global pharmaceuticals and wellness industry, has reported its financial results for the Second Quarter (Q2) and Half Year (H1) of FY25, indicating a notable upward trend in its performance. Financial Highlights from Q2 FY25...

Continue Reading
Foresee Pharmaceuticals Launches Phase 2 Study for Mirivadelgat

Updated Category News Views 221

Foresee Pharmaceuticals Advances Treatment Options for PH-ILD Foresee Pharmaceuticals has recently marked a significant milestone by announcing the dosing of the first patient in its Phase 2 WINDWARD study. This critical study aims to assess the efficacy and safety of mirivadelgat, a novel oral medication designed for individuals suffering from pulmonary...

Continue Reading
Suki Secures $70 Million to Enhance AI Healthcare Solutions

Updated Category News Views 101

Suki's Impressive Funding Round Suki, an innovative healthcare startup, has successfully raised $70 million in its Series D funding round. This funding brings the company's total capital raised to an impressive $165 million. The news marks a significant step forward for Suki as it seeks to enhance its AI-assisted offerings aimed at reducing the administrative burdens...

Continue Reading